The Prevention of Thromboembolic Complications Associated With Coil Embolization

Completed

• Conditions: Thromboembolic Stroke; Aspirin; Prevention; Clopidogrel; Coil Embolization
• Interventions: Drug: Aspir-Low Pill

• Registration Number: NCT05512546
• Lead Sponsor: Muhammad Hassan

Brief Summary

Clopidogrel has been to be reported to be superior to aspirin for the prevention of thromboembolic complications associated with coil embolization in patients with ruptured aneurysms.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-10
• Primary Completion: 2020-02-10
• Study Completion: 2020-12-10
• Status Verified: 2022-08
• Study First Submitted: 2022-08-21
• Study First Submitted QC: 2022-08-21
• Last Update Submitted: 2022-08-21
• Study First Posted: 2022-08-23
• Last Update Posted: 2022-08-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• All the patients enrolled in the study underwent MRI and Angiography.
• Participants included in the study were confirmed on assessment, and verified for ruptured aneurysm by imaging using either computed tomography (CT) or MRI.

Exclusion Criteria

• Patients with any history of sensitivity or reaction to aspirin, or any contraindication for MRI, were excluded from the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Aspirin Group	Aspir-Low Pill	patients were prescribed 75 mg/day of either aspirin for 6 months
Clopidogrel Group	Aspir-Low Pill	75mg/day prescribed for 6 months

Primary Outcome Measures

Name	Time	Method
High Intensity Areas	3 months	Post Procedural

Secondary Outcome Measures

Name	Time	Method
High Intensity Areas	at 6 months	Post procedural

Trial Locations

Locations (1)

Umair Rasheed; 🇵🇰 Lahore, Punjab, Pakistan